Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/Stenting A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI]

Gregory Lip, K Huber, F Andreotti, H Arnesen, KJ Airaksinen, T Cuisset, Paulus Kirchhof, F Marin

Research output: Contribution to journalReview article

258 Citations (Scopus)

Abstract

There remains uncertainty over optimal antithrombotic management strategy for patients with atrial fibrillation (AF) presenting with an acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Clinicians need to balance the risk of stroke and thromboembolism against the risk of recurrent cardiac ischaemia and/or stent thrombosis, and the risk of bleeding. This consensus document comprehensively reviews the published evidence and presents a consensus statement on a 'best practice' antithrombotic therapy guideline for the management of antithrombotic therapy in such AF patients.
Original languageEnglish
Pages (from-to)13-28
Number of pages16
JournalThrombosis and Haemostasis
Volume103
Issue number1
DOIs
Publication statusPublished - 1 Jan 2010

Keywords

  • percutaneous coronary intervention
  • acute coronary syndrome
  • warfarin
  • stenting
  • antithrombotic therapy
  • Arial fibrillation

Fingerprint

Dive into the research topics of 'Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/Stenting A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI]'. Together they form a unique fingerprint.

Cite this